Guardant360 CDx

Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics.

Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening.

Guardant Health

‘Revolutionizing Colorectal Cancer Screenings’: Our Chief Medical Officer Dr. Craig Eagle highlights why developing accessible testing to screen for #ColorectalCancer is crucial, and how blood-based screening can overcome current barriers. 

"When it's caught early, you can have up to 91% survival at five years. And we're talking about cancer, which can be scary. If it's left to spread, that's a lot wider, the chance of surviving that five years drops down."

Patients and doctors agree that blood tests could help close the #ColorectalCancer screening gap in new The Harris Poll survey results announced during Colorectal Cancer Awareness Month.

We commissioned the survey to better understand the reasons why people decide to get screened or not.

We are looking forward to the 3rd annual NeauxCancer Conference by Cancer Advocacy Group of Louisiana (CAGLA) where our Co-CEO AmirAli Talasaz will participate as a keynote speaker.

We're proud to sponsor the 8th Annual Liquid Biopsy for Precision Oncology Summit later this month in San Diego. Our Clinical Evidence Director Thereasa Rich will help kick off the summit by delivering a talk on the potential for MRD and longitudinal monitoring tests to accelerate clinical trials.

Later in the day, our team will participate on a panel about advancing precision oncology globally through improved access to liquid biopsy.

More details: https://lbx-summit.com/

As part of #BlackHistoryMonth, we asked Guardant Health employees to share what the month means to them. For our Clinical Oncology Specialist Candice, it's a time to look back and celebrate past achievements while being cognizant of the work that still needs to be done.

What does Black History Month mean to you?

Freenome is a competitor of Guardant Health in the precision oncology sector, offering cancer screening and monitoring services.

Freenome

C2i Genomics is a competitor of Guardant Health specializing in genomics and cancer analytics.

C2i Genomics

Owlstone Medical competes with Guardant Health in the field of cancer diagnostics and precision medicine.

Owlstone Medical

Invitae is a key competitor of Guardant Health, providing genetic testing and genomic information services.

Invitae

QIAGEN is a prominent competitor of Guardant Health, specializing in sample and assay technologies for molecular diagnostics.

QIAGEN

Tempus competes with Guardant Health in the field of precision medicine and data analytics for cancer care.

Tempus

Guardant Health is a precision oncology company that provides blood and tissue tests, data sets, and analytics to help patients at all stages of cancer live longer and healthier lives through the power of blood tests and the data they unlock.

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Guardant Health, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 8, 2024 4:40 AM	0cbac685
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 4:40 AM	463ba693
company summary	general
signals	general	Mar 8, 2024 4:40 AM	60738600
crunchbase trigger	general	Nov 27, 2024 12:50 PM	f9f7e9ca
crunchbase profile	general	Nov 27, 2024 1:28 PM	b04c231c
li profile	general	Mar 8, 2024 4:40 AM	6154ca9d
translate crunchbase fundingrounds	general
peers	general	Mar 8, 2024 4:40 AM	5d718fae
news basic	general	Mar 8, 2024 4:40 AM	e82378f4
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:GUARDANTHEALTH

Guardant Health, Inc.

Last Close

30.98

22/11 21:00

Market Cap

3.38B

Beta: -

Volume Today

2.14M

Avg: -